Non-Postoperative Pain Management Outlook in Major Markets, 2026-2036 | Industry Poised for Growth as Non-Opioid Therapies and Advanced Drug Delivery Drive Innovation
Dublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "Non-Postoperative Pain Management - Market Insights, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.
The moderate-to-severe non-postoperative acute pain management market across the seven major markets (7MM)-the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan-reached approximately USD 3.40 billion in 2025. The market is projected to expand at a compound annual growth rate of approximately 10% from 2026 to 2036, supported by demand for rapid-acting non-opioid therapies, increasing acute pain incidence, and continued innovation in targeted drug delivery.
The report provides a comprehensive assessment of historical and forecasted epidemiology, treatment practices, market size, competitive dynamics, patient uptake, pricing, reimbursement, and emerging therapies across the 7MM. The analysis covers the 2022-2036 period and evaluates the commercial potential of current and pipeline treatments.
Key Non-Postoperative Pain Management Market Insights
Shift Toward Multimodal and Non-Opioid Pain Management
Non-postoperative pain treatment increasingly combines pharmacological and non-pharmacological interventions. Common pharmacological options include nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, topical therapies, anticonvulsants, ketamine, corticosteroids, local anesthetics, and short-course opioids for selected patients. Physical therapy, cognitive-behavioral therapy, acupuncture, transcutaneous electrical nerve stimulation, cold therapy, compression, elevation, immobilization, breathing exercises, and rehabilitation may also be integrated into individualized treatment plans.
Multimodal analgesia remains central to clinical practice because therapies with different mechanisms of action can provide additive or synergistic pain relief while limiting exposure to high-dose monotherapy. The approach is particularly relevant as healthcare systems seek to reduce opioid-related adverse effects, dependence, misuse, and unnecessary prescribing.
Real-world evidence indicates that approximately 42% to 71% of prescribed opioids remain unused, while 16% to 29% of patients experience adverse effects. These findings are accelerating the adoption of opioid-sparing strategies and creating opportunities for therapies that deliver rapid, reliable, and sustained pain control without increasing opioid exposure.
NSAIDs are expected to retain a prominent role in acute pain management, although gastrointestinal, renal, and cardiovascular risks require appropriate patient selection and monitoring. Acetaminophen is also projected to maintain broad utilization, while adjunctive therapies and topical formulations may gain adoption as clinicians increasingly apply mechanism-based and patient-specific treatment strategies.
Unmet Needs and Market Growth Drivers
A major unmet need remains the availability of rapid-onset, non-opioid therapies with consistent efficacy, convenient administration, and favorable tolerability. This challenge is especially important in migraine, where delayed onset, symptom recurrence, variable response, nausea, and difficulty swallowing may affect treatment outcomes and adherence.
Additional gaps include inconsistent implementation of multimodal pain management guidelines, limited adoption of behavioral interventions, diagnostic variability, insufficient condition-specific research, and differences in access to treatment. Addressing these barriers could improve functional outcomes, reduce progression to persistent pain, and support broader uptake of integrated pain management strategies.
Market growth is also being driven by innovation in self-administered, fast-acting, and patient-centric formulations. Oral dissolvable films, intranasal powders, transdermal patches, and other targeted delivery technologies are intended to improve convenience, treatment initiation, adherence, and clinical response.
Approved and Emerging Non-Postoperative Pain Therapies
ATZUMI, a dihydroergotamine nasal powder from Satsuma Pharmaceuticals, is indicated for the acute treatment of migraine with or without aura in adults. The therapy uses the proprietary SMART platform to support intranasal delivery through a portable device.
SYMBRAVO from Axsome Therapeutics combines meloxicam and rizatriptan in a single-dose oral therapy. Its dual-mechanism formulation targets inflammatory and neurovascular pathways and is designed to provide rapid and sustained migraine relief while reducing symptom recurrence.
Among pipeline candidates, Teikoku Pharma's TK-254Rx is an investigational esflurbiprofen 1.5% hydrogel patch being evaluated for acute strains, sprains, and contusions. The once-daily patch uses proprietary Hydrohesive technology and is designed for treatment lasting up to seven days.
RizaFilm, developed by IntelGenx and associated with Gensco Pharma, is an oral thin-film formulation of rizatriptan benzoate. It can be administered without water and is intended to facilitate timely migraine treatment. In May 2025, Gensco Pharma acquired global rights and intellectual property associated with the rizatriptan oral dissolvable film, marketed under the RizaFilm and RizaPort brands.
Companies active in the non-postoperative pain management market include Teikoku Pharma, Gensco Pharma, Scilex Holding Company, Cessatech A/S, Allodynic Therapeutics, Biohaven Therapeutics, Vaneltix Pharma, Axsome Therapeutics, and other established and emerging developers.
Recent Non-Postoperative Pain Management Developments
Competitive Landscape, Drug Uptake, and Market Access
Therapy uptake through 2036 will depend on efficacy, safety, route of administration, onset and duration of action, regulatory timing, pricing, reimbursement, competitive positioning, and the size of the addressable patient population. NSAIDs and acetaminophen are expected to maintain substantial utilization, while opioid use will likely become increasingly selective. Topical agents, anticonvulsants, ketamine, and other adjunctive treatments may experience moderate growth as multimodal analgesia becomes more widely implemented.
Market access will remain closely linked to cost-effectiveness, payer coverage, out-of-pocket costs, formulary placement, and the clinical value demonstrated by emerging therapies. Developers entering the non-postoperative pain management market will need to establish clear differentiation through rapid onset, sustained efficacy, improved tolerability, convenient administration, or reduced opioid requirements.
Report Coverage and Strategic Value
The report includes epidemiology-based bottom-up forecasting, an 11-year market outlook, patient burden analysis, total addressable market estimates, therapy-level market share projections, pricing and analogue assessments, peak patient share analysis, and drug adoption forecasts. It also examines current treatment practices, unmet medical needs, clinical development, competitive positioning, and market attractiveness across North America, Europe, and Japan.
Qualitative analysis includes SWOT and conjoint assessments based on efficacy, safety, administration frequency, route of administration, order of entry, probability of success, and addressable patient population. Insights from more than 15 key opinion leaders and subject-matter experts support the evaluation of prescribing behavior, treatment adherence, therapy switching, access barriers, epidemiology, and pipeline priorities.
The non-postoperative pain management market is expected to evolve substantially through 2036 as clinical practice moves toward safer, more balanced, and mechanism-based treatment. Rising patient burden, opioid safety concerns, persistent gaps in migraine care, and advances in drug delivery are likely to create significant opportunities for companies developing rapid-acting, non-opioid, and patient-centric therapies.
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this report visit https://www.researchandmarkets.com/r/12jsrz
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.